Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition

     Novus International And Verenium Announce Important Progress In The
          Development Of Novel Enzymes For Animal Health & Nutrition

-- First NSP enzyme candidates selected; next-generation phytase product
development on track for initial launch in 2013 --

PR Newswire

ST. LOUIS and SAN DIEGO, Jan. 30, 2013

ST. LOUIS and SAN DIEGO, Jan. 30, 2013 /PRNewswire/ --Novus International
Inc., a leading manufacturer of animal nutrition and health products and
Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology
company focused on the development and commercialization of high-performance
enzymes, today announced significant steps forward in their collaboration's
progress toward commercializing its suite of next-generation animal nutrition
enzymes. The two companies, which entered into a strategic partnership in
2011, recently selected lead enzyme candidates for the development of the
collaboration's suite of non-starch polysaccharide (NSP) products designed to
enhance the digestibility of feedstuffs in monogastric diets. Additionally,
the two companies announced that their next-generation phytase remains on
track and the commercial launch of the product into select geographies is
targeted in 2013.


"Our collaboration with Novus and the development of a suite of
next-generation enzyme products for animal nutrition are progressing very
positively," said James Levine, President and Chief Executive Officer at
Verenium. "Through this important collaboration, we are able to further
diversify our product portfolio and gain access to the broader animal health
and nutrition market for enzymes. Importantly, the market opportunity for
phytase and NSP enzymes is large and rapidly growing and through Novus'
extensive industry expertise and global market reach we expect to be able to
capture a significant share of this market with our superior performing enzyme
product offerings."

Building on Novus's existing CIBENZA® portfolio these new products hold great
promise and the collaboration is working to bring quality solutions for feed
cost optimization and gut health in the poultry industry to help solve issues
at the nutrition level, before they reach production and processing.

"We are very pleased with the progress this collaboration has achieved to
date," notes Novus International Specialty Business President and Chief
Operating Officer Francois Fraudeau. "Verenium's unique enzyme development
capabilities are allowing us to create new, versatile solutions for our
customers that offer improved environmental and economic sustainability. We
look forward to continuing to advance this suite of high-performance enzyme
products toward commercialization."

Upcoming Events

Novus International, Inc., will be exhibiting at the International Production
and Processing Expo (IPPE) in Atlanta, Georgia. Representatives from Novus and
Verenium will be at the Novus booth in the Georgia World Congress Center Hall
A, Booth 1529 and Novus is hosting several other events in support of the
poultry industry during the week.

  oWednesday January 30 from 9-10AM: Breakfast at Booth #1529
  oWednesday January 30 at 5PM: Cocktail Party at the Omni Hotel Dogwood Room
    A-M1 North Tower

About The Animal Health and Nutrition Market

Enzymes are used in the animal health and nutrition market to allow livestock,
poultry, aquaculture and companion animals to more readily digest and absorb
the nutrients naturally occurring in grains and protein meals.According to
industry reports, enzymes in the animal health and nutrition market are
experiencing remarkable growth due to their ability to provide better
nutrition and an improved environmental impact.Global sales of animal feed
enzymes are estimated to have reached nearly $600 million in 2012, and are
expected to grow 6 to 7 percent annually to reach more than $700 million by
2016, making it one of the largest and fastest growing markets for industrial
enzymes. Given the trends of global population growth, increased meat
consumption in emerging markets and increased grain prices leading to higher
feed costs for producers, enzymes are an effective means of improving the
sustainability of animal production both economically and environmentally.

About Novus International, Inc.

Novus International, Inc. is headquartered in metropolitan St. Louis,
Missouri, U.S.A. and serves customers in nearly 100 countries around the
world. A global leader in developing animal health and nutrition solutions,
Novus's products include ALIMET^® and MHA^® feed supplements, ACTIVATE^®
nutritional feed acid, ACIDOMIX^® preservative premixture, ADVENT^®
coccidiosis control, MINTREX^® chelated trace minerals, SANTOQUIN^® feed
preservative, MERA™ MET aquaculture feed additive, AGRADO^® feed ingredient
and many other specialty ingredients. Arenus^® ( is a division
of Novus Nutrition Brands, LLC (a subsidiary of Novus International, Inc.)
that focuses on developing health and dietary supplements for the equine and
companion animal markets. Stratum® Nutrition, a division of Novus Nutrition
Brands, LLC, focuses on human nutrition through specialty and functional
ingredients for manufacturers of foods, beverages and dietary supplements
( Novus is privately owned by Mitsui & Co. (U.S.A.),
Inc. and Nippon Soda Co., Ltd. For more information visit

AGRADO are trademarks of Novus International, Inc. and are registered in the
United States and other countries. ^®ADVENT is a trademark of Viridus Animal
Health, LLC, and is registered in the United States and other countries.
^®ARENUS is a registered trademark of Novus Nutrition Brands, LLC. ^®STRATUM
NUTRITION is a trademark of Novus Nutrition Brands, LLC, and is registered in
the United States and other countries. ™MERA and SOLUTIONS SERVICE
SUSTAINABILITY are trademarks of Novus International, Inc. ^ © 2012 Novus
International, Inc. All rights reserved.

About Verenium

Verenium, an industrial biotechnology company, is a global leader in
developing high-performance enzymes. Verenium's tailored enzymes are
environmentally friendly, making products and processes greener and more
cost-effective for industries, including the global food and fuel markets.

Forward Looking Statements for Verenium

Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include, but are not limited to, statements related to Verenium's ability to
commercialize its products, enhance its manufacturing capabilities, capture
near-term and longer-term growth and prospects, and reach profitability. Such
statements are only predictions, and actual events or results may differ
materially from those projected in such forward-looking statements. Factors
that could cause or contribute to the differences include, but are not limited
to, risks associated with Verenium's strategic focus, technologies, products
and product candidates and product pipeline (including Verenium's ability to
identify, develop and commercialize new products and product candidates,
either independently or with collaborators or partners, and market demand for
those products and product candidates), dependence on patents and proprietary
rights, protection and enforcement of its patents and proprietary rights, the
commercial prospects of the industries in which Verenium operates and sells
products, Verenium's dependence on manufacturing and/or license agreements,
its ability to achieve milestones under existing and future collaboration
agreements, the ability of Verenium and its partners to commercialize its
technologies and products (including by obtaining any required regulatory
approvals) using Verenium's technologies, the timing for launching any
commercial products and projects, the ability of Verenium and its
collaborators to market and sell any products that it or they commercialize,
the development or availability of competitive products or technologies, the
future ability of Verenium to enter into and/or maintain collaboration and
joint venture or partnership agreements and licenses on a timely basis or at
all, and risks and other uncertainties more fully described in Verenium's
filings with the Securities and Exchange Commission, including, but not
limited to, Verenium's annual report on Form 10-K for the year ended December
31, 2011 and any updates contained in its subsequently filed quarterly reports
on Form 10-Q . These forward-looking statements speak only as of the date
hereof, and Verenium expressly disclaims any intent or obligation to update
these forward-looking statements.

Contacts for Verenium:

Sarah Carmody
Sr. Manager, Corporate Communications

Contacts for Novus:

Tracy Barfield
Executive Manager, Marketing Communications

SOURCE Verenium Corporation

Press spacebar to pause and continue. Press esc to stop.